Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Androes

Vascular Surgery Greenville, SC Medical Doctor

NPI 1942200407 CMS profile 360624

13 Edgewood Dr, Ste C300, Greenville, SC 29605

Open in the dashboard

General payments

$9,036

240 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$45,350 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Mark Androes of Greenville, SC is reported in the CMS Open Payments database as having received $9,036 across 240 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $45,350 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 65th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,182 69
2024 General $1,123 40
2023 General $1,373 44
2022 General $2,798 41
2021 General $636 16
2020 General $408 12
2019 General $517 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Androes
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Mark Androes were reported at $2,182. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Mark Androes Vascular Surgery median Middle half National median
2019 $517 $796 $226–$2,363 $163
2020 $408 $348 $118–$1,110 $114
2021 $636 $471 $158–$1,421 $132
2022 $2,798 $725 $222–$2,183 $149
2023 $1,373 $836 $257–$2,440 $160
2024 $1,123 $909 $252–$2,619 $164
2025 $2,182 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $3,421 39 payments
  2. Cook Medical LLC $1,992 81 payments
  3. Shockwave Medical, Inc $527 18 payments
  4. Medtronic Vascular, Inc. $480 7 payments
  5. Medtronic, Inc. $425 10 payments
  6. Stryker Corporation $252 5 payments
  7. Teleflex LLC $202 2 payments
  8. Boston Scientific Corporation $191 12 payments
  9. Philips Electronics North America Corporation $139 7 payments
  10. Terumo Medical Corporation $130 6 payments
  11. Other $1,277 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,217 235 payments
  2. Travel and Lodging $1,819 5 payments
Products named General payments · program years 2019–2025
  1. GORE TAG Thoracic Endoprosthesis $2,231 8 payments
  2. Zilver PTX $703 20 payments
  3. Endurant $477 6 payments
  4. COOK $410 14 payments
  5. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Lithoplasty $294 12 payments
  6. GORE VIABAHN VBX Balloon Expandable Endo $252 7 payments
  7. ROSEN $246 10 payments
  8. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Cardiology $203 5 payments
  9. GORE TAG Thoracic Branch Endoprosthesis $191 3 payments
  10. MANTA $187 1 payment
  11. Other $3,908 161 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

320

Median for Vascular Surgery: 122

Drug cost

$16,553

Median for Vascular Surgery: $14,135

Branded share of claims

37.2%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 16 $11,334
Cilostazol Generic 91 $2,219
Duloxetine Hcl Generic 52 $1,405
Clopidogrel Clopidogrel Bisulfate Brand 103 $1,030
Oxycodone Hcl Generic 30 $288
Gabapentin Generic 16 $268
Prednisone Generic 12 $9

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 120 billing codes

Paid by Medicare

$98,163

Medicare's payments for the services billed

Medicare patients

595

Average age 75

Services billed

1,285

211 women, 384 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 51%
Arthritis 47%
Chronic kidney disease 43%
Diabetes 40%
Heart failure 35%
Atrial fibrillation 29%
Depression 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

240 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record